Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers. Over the next few years, immuno ...

Q4 2024 diluted net income per share was $ ... but analysts expressed increased concerns about competitive pressures on EYLEA ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... which was taken from Insider Monkey’s Q4 ...

Then I take a look at the company’s new dividend and buyback strategy, and how that gives me confidence in Regeneron’s long-term cash flow capabilities. In Q4 of 2024, Regeneron reported $1.5B ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Explore Regeneron Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for REGN. Sanofi plans $20 billion US investment by 2030 to expand R&D and ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Citigroup on May 14, 2025. The analyst firm set a price target for $700.00 expecting REGN to rise to within 12 ...

Compared to Q4 2024, Q1 2025 saw a decline in EYLEA net ... pressures and potential delays in key product approvals. Regeneron faced mixed results in Q1 2025 with challenges in its retinal ...

Regeneron Pharmaceuticals has announced a new manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies to enhance its production capacity for biologic medicines at Fujifilm's ...

Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to manufacture and supply bulk drug product of Regeneron’s ...